Ecnoglutide tablets for overweight or obesity in Chinese adults
Tests ecnoglutide tablets against placebo in Chinese adults with overweight or obesity.
Key facts
- Who runs it
- Hangzhou Sciwind Biosciences Co., Ltd.
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- A Study to Evaluate the Safety and Efficacy of Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity
- Status
- Not yet recruiting
- Phase
- Phase 2
- People taking part
- 180 people, planned
- Started
- 10 Nov 2026
- Expected to end
- 28 Jan 2028
- Type of study
- Interventional, 5 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- ecnoglutide tablet
- placebo with matching dosage
- Record updated
- 10 November 2026
Who can take part
The trial is looking for adults aged 18 to 65 with overweight or obesity, with or without a weight-related health problem, who have not had a big recent change in body weight.
- Age
- 18 Years to 65 Years
- Sex
- All sexes can join.
- Disease stage
- BMI of 28.0 kg/m^2 or more, with or without other health problems. Or BMI from 24.0 kg/m^2 up to less than 28.0 kg/m^2 with at least one health problem such as prediabetes, high blood pressure, abnormal blood fats, fatty liver, sleep apnea or weight-bearing joint pain.
- Earlier treatment
- No major stomach or bowel surgery and no weight-loss (metabolic) surgery in the past; gallbladder or appendix removal is allowed. No major surgery planned during the study.
- Biomarker or test result
- Body weight changed by less than 5% in the 3 months before consent (self-reported). HbA1c below 6.5% (48 mmol/mol), fasting blood glucose below 7.0 mmol/L (126 mg/dL) and 2-hour OGTT blood glucose below 11.1 mmol/L (200 mg/dL) at screening.
- Main reasons for not taking part
- Overweight or obesity caused by a hormone disorder, such as Cushing's syndrome
- Other significant hormone or thyroid disease, including medullary thyroid carcinoma or personal or family history of MEN2
- Significant heart or brain blood vessel disease in the 6 months before screening
- Significant stomach or bowel disease in the 6 months before screening
- Blood sugar levels in the diabetes range at screening
Show the full registry criteria (9)Hide the full registry criteria
Who can take part
- At the time of informed consent, BMI≥28.0 kg/m\^2 regardless of comorbidities, or 24.0kg/m\^2≤BMI<28.0 kg/m\^2 with at least one of the comorbidities (prediabetes, hypertension, dyslipidemia, fatty liver, obstructive sleep apnea syndrome, weight-bearing joint pain, etc.)
- Self-declaration of body weight change <5% within 3 months prior to informed consent
Who cannot take part
- Diagnosis of cardiovascular or cerebrovascular diseases with clinical significance within 6 months prior to screening, including but not limited to myocardial infarction, coronary angioplasty or bypass surgery, valvular heart disease or valve repair, unstable angina, transient ischemic attack, acute stroke, acute coronary syndrome, congestive heart failure classified as New York Heart Association class III or IV, clinically significant arrhythmias requiring treatment, and cerebrovascular accidents, etc
- Diagnosis of gastrointestinal diseases with clinical significance within 6 months prior to screening, including but not limited to inflammatory bowel disease, active ulcers, irritable bowel syndrome, celiac disease, dyspepsia, clinical gastric emptying abnormalities (such as pyloric obstruction), etc
- Diagnosis of overweight or obesity due to endocrine disorders , such as Cushing's syndrome
- Diagnosis of other endocrine disorders with clinical significance, including but not limited to hyperthyroidism or hypothyroidism, thyroid nodules (imaging shows C-TIRADS≥ class 4A), Medullary thyroid carcinoma, or personal or family history of type 2 multiple endocrine tumor syndrome (MEN2), etc
- History of major gastrointestinal surgery (except cholecystectomy or appendectomy), or metabolic surgery, or plan to undergo major surgery during the study period
- HbA1c ≥6.5% or fasting blood glucose ≥7.0 mmol/L, or OGTT 2-hour blood glucose ≥11.1 mmol/L, at screening
- Clinical laboratory test results with clinical significance
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Weight management
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The aim of the study is to evaluate the safety and efficacy of oral ecnoglutide tablets in Chinese participants with overweight or obesity
The 5 groups in the trial
- oral ecnoglutide dose 1Treatment being tested
once daily from week1 to week 8, then once weekly from week 9 to week 24
Treatment: ecnoglutide tablet
- oral ecnoglutide dose 2Treatment being tested
once daily from week1 to week 8, then once weekly from week 9 to week 24
Treatment: ecnoglutide tablet
- oral ecnoglutide dose 3Treatment being tested
once daily from week1 to week 12, then once weekly from week 13 to week 24
Treatment: ecnoglutide tablet
- PlaceboPlacebo, for comparison
once daily from week1 to week 8 or week 12, then once weekly from week 9 or week 13 to week 24
Treatment: placebo with matching dosage
- oral ecnoglutide dose 4Treatment being tested
once daily from week1 to week 12, then once weekly from week 13 to week 24
Treatment: ecnoglutide tablet
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Safety and Efficacy of Oral Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity
- Plain-language title
- Ecnoglutide tablets for overweight or obesity in Chinese adultsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Criteria questions
- Built from NCT07929298, who can take part
- Record updated
- 10 November 2026